A Multicenter, Open-label Phase I Clinical Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SHR-5495 for Injection in Patients With Advanced Malignancies
Latest Information Update: 13 Nov 2023
At a glance
- Drugs SHR 5495 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Suncadia Biopharmaceuticals
- 02 Nov 2023 Status changed from not yet recruiting to recruiting.
- 06 Oct 2023 New trial record